Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
Vaccine(2015)
Abstract
•Some children may not receive pneumococcal conjugate vaccine (PCV) as infants.•PCV13 was evaluated in pneumococcal vaccine-naïve children aged 7 months to 5 years.•Age-specific “catch-up” vaccination schedules were evaluated.•The proportion of immunological responders ranged from 88% to 100% for all 13 serotypes.•PCV13 was generally well-tolerated; trend for greater tenderness in older subjects.
MoreTranslated text
Key words
Pneumococcal conjugate vaccine,Vaccine clinical evaluation,Immunization,Immunogenicity
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined